Waldencast sells Obagi Medical to Bridgepoint for up to $460M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Waldencast Announces Completion of the Sale of Obagi Medical to Bridgepoint
July 30, 2026 4:30 PM EDTLONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (Waldencast or the Company) today announced that it completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business (Obagi Medical) to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million (subject to negotiated deductions and customary adjustments based on closing cash, closing indebtedness, net working capital and transaction expenses), marking a significant step in Waldencasts strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup.
As previously... More
